

Claim

1. A pharmaceutical composition for treating cerebral infarction, which comprises a compound having mGluR1 antagonism as an active ingredient.

2. The pharmaceutical composition according to claim 1, which is for treating cerebral infarction at the acute stage.

3. The pharmaceutical composition according to claim 1, which comprises a compound having selective mGluR1 antagonism as an active ingredient.

4. The pharmaceutical composition according to claim 3, wherein the compound having selective mGluR1 antagonism is 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide dihydrochloride.

add
B⁶ 7

add
B²